StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for TNDM yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $13.15 | $13.53 | +2.89% | 4.7M |
| 05-19 | $13.53 | $13.86 | +2.44% | 2.0M |
| 05-20 | $13.89 | $15.04 | +8.28% | 1.7M |
| 05-21 | $14.94 | $15.76 | +5.49% | 2.8M |
| 05-22 | $15.74 | $14.96 | -4.92% | 2.0M |
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $247.22M | $1.01B | $724.35M | $475.10M |
Operating Income | $-17.43M | $-187.26M | $-195.55M | $-172.69M |
Net Income | $-20.39M | $-204.71M | $-204.12M | $-182.96M |
EPS (Diluted) | $-0.30 | $-3.04 | $-3.04 | $-2.74 |
Total Assets | $1.15B | $881.11M | $874.65M | $875.74M |
Total Liabilities | $1.02B | $725.94M | $741.69M | $742.45M |
Cash & Equivalents | $179.32M | $90.63M | $91.95M | $64.11M |
Free Cash Flow OCF − CapEx | $4.79M | $-29.67M | $-32.77M | $-36.95M |
Shares Outstanding | 68.50M | 68.29M | 67.77M | 67.53M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.